Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis

   Active, not recruiting · Phase 3 · Acute Gastroenteritis

   NCT06592794 · ModernaTX, Inc. · 186 U.S. investigators

   $117.0Mresearch payments

2. A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age

   Completed · Phase 3 · Seasonal Influenza

   NCT06602024 · ModernaTX, Inc. · 188 U.S. investigators

   $83.4Mresearch payments

3. A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight

   Completed · Phase 1 · Healthy

   NCT06440980 · Eli Lilly and Company · 7 U.S. investigators

   $79.8Mresearch payments

4. A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

   Active, not recruiting · Phase 3 · Atherosclerotic Cardiovascular Disease (ASCVD)

   NCT06292013 · Eli Lilly and Company · 253 U.S. investigators

   $61.8Mresearch payments

5. A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

   Active, not recruiting · Phase 3 · Alzheimer's Disease

   NCT06653153 · Eli Lilly and Company · 123 U.S. investigators

   $55.8Mresearch payments

6. Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

   Recruiting · Phase 2, Phase 3 · End Stage Kidney Disease

   NCT05485961 · Csl Behring · 183 U.S. investigators

   $42.4Mresearch payments

7. A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

   Active, not recruiting · Phase 3 · Alzheimer Disease

   NCT05026866 · Eli Lilly and Company · 150 U.S. investigators

   $41.2Mresearch payments

8. A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)

   Active, not recruiting · Phase 3 · Neovascular Age-Related Macular Degeneration

   NCT06491914 · Regeneron Pharmaceuticals, Inc. · 60 U.S. investigators

   $37.3Mresearch payments

9. A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age

   Completed · Phase 3 · Influenza, Human

   NCT06087640 · Seqirus USA Inc · 116 U.S. investigators

   $37.3Mresearch payments

10. Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

    Active, not recruiting · Phase 3 · Chronic Lymphocytic Leukemia

    NCT03701282 · AbbVie Inc. · 1 U.S. investigator

    $36.7Mresearch payments

11. A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation

    Active, not recruiting · Phase 2 · Obesity

    NCT06299098 · Regeneron Pharmaceuticals, Inc. · 67 U.S. investigators

    $32.0Mresearch payments

12. The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

    Active, not recruiting · Phase 3 · Atherosclerotic Cardiovascular Disease (ASCVD)

    NCT06383390 · Eli Lilly and Company · 234 U.S. investigators

    $27.9Mresearch payments

13. A Study of LY3537031 in Overweight, Obese, and Healthy Participants

    Active, not recruiting · Phase 1 · Overweight

    NCT06606106 · Eli Lilly and Company · 6 U.S. investigators

    $27.2Mresearch payments

14. Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

    Active, not recruiting · Phase 3 · CLL

    NCT06073821 · Beigene, Ltd. · 44 U.S. investigators

    $26.0Mresearch payments

15. A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants

    Active, not recruiting · Phase 2, Phase 3 · Hypothyroidism

    NCT06345339 · AbbVie Inc. · 140 U.S. investigators

    $24.7Mresearch payments

16. A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age

    Completed · Phase 2, Phase 3 · Respiratory Syncytial Virus

    NCT05127434 · ModernaTX, Inc. · 117 U.S. investigators

    $22.5Mresearch payments

17. Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

    Active, not recruiting · Phase 3 · Chronic Lymphocytic Leukemia

    NCT03737981 · AbbVie Inc. · 1 U.S. investigator

    $22.2Mresearch payments

18. Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia

    Completed · Phase 3 · Schizophrenia

    NCT06572449 · E.r. Squibb & Sons, L.l.c. · 4 U.S. investigators

    $19.6Mresearch payments

19. Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older

    Active, not recruiting · Phase 1, Phase 2 · Human Metapneumovirus Immunization

    NCT06686654 · Sanofi Pasteur Inc. · 24 U.S. investigators

    $17.9Mresearch payments

20. A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

    Active, not recruiting · Phase 3 · Obesity

    NCT06662383 · Eli Lilly and Company · 42 U.S. investigators

    $17.9Mresearch payments

21. A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

    Active, not recruiting · Phase 3 · Non-Alcoholic Fatty Liver Disease

    NCT04951219 · Madrigal Pharmaceuticals · 144 U.S. investigators

    $17.5Mresearch payments

22. A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

    Active, not recruiting · Phase 3 · Breast Neoplasms

    NCT05514054 · Eli Lilly and Company · 128 U.S. investigators

    $16.6Mresearch payments

23. A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

    Active, not recruiting · Phase 3 · Alzheimer's Disease

    NCT05738486 · Eli Lilly and Company · 44 U.S. investigators

    $16.1Mresearch payments

24. A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

    Active, not recruiting · Phase 2 · Obesity

    NCT06643728 · Eli Lilly and Company · 14 U.S. investigators

    $15.5Mresearch payments

25. A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

    Terminated · Phase 3 · Cytomegalovirus Infection

    NCT05085366 · ModernaTX, Inc. · 158 U.S. investigators

    $15.0Mresearch payments

26. A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

    Completed · Phase 3 · Obesity

    NCT05929066 · Eli Lilly and Company · 49 U.S. investigators

    $14.9Mresearch payments

27. Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Active, not recruiting · Phase 3 · Anemia

    NCT02048813 · AbbVie Inc. · 1 U.S. investigator

    $14.2Mresearch payments

28. A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

    Active, not recruiting · Phase 3 · Dermatitis Atopic

    NCT06407934 · Sanofi US Services Inc. · 89 U.S. investigators

    $13.9Mresearch payments

29. A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

    Active, not recruiting · Phase 3 · Obesity

    NCT06859268 · Eli Lilly and Company · 30 U.S. investigators

    $13.4Mresearch payments

30. A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

    Active, not recruiting · Phase 3 · Obesity

    NCT05556512 · Eli Lilly and Company · 198 U.S. investigators

    $12.5Mresearch payments

31. A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults

    Active, not recruiting · Phase 1, Phase 2 · Epstein-Barr Virus Infection

    NCT05164094 · ModernaTX, Inc. · 64 U.S. investigators

    $12.3Mresearch payments

32. A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib

    Active, not recruiting · Phase 3 · B-cell Malignancies

    NCT04170283 · Beone Medicines Ltd. · 29 U.S. investigators

    $12.0Mresearch payments

33. A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity

    Completed · Phase 1 · Overweight

    NCT06916065 · Eli Lilly and Company · 3 U.S. investigators

    $11.8Mresearch payments

34. A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

    Completed · Phase 3 · Alzheimer's Disease

    NCT05463731 · Eli Lilly and Company · 67 U.S. investigators

    $11.7Mresearch payments

35. A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

    Completed · Phase 2 · Obesity

    NCT06373146 · Eli Lilly and Company · 23 U.S. investigators

    $11.6Mresearch payments

36. A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease

    Completed · Phase 2 · Alzheimer Disease

    NCT06538116 · Eli Lilly and Company · 46 U.S. investigators

    $11.5Mresearch payments

37. Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies

    Active, not recruiting · Phase 1 · Mature B-Cell Malignancies

    NCT04277637 · Beone Medicines Ltd. · 13 U.S. investigators

    $10.6Mresearch payments

38. A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older

    Completed · Phase 1, Phase 2 · Influenza

    NCT06744205 · Sanofi Pasteur Inc. · 23 U.S. investigators

    $10.5Mresearch payments

39. Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

    Recruiting · Phase 3 · Psychosis Associated With Alzheimer's Disease

    NCT05980949 · E.r. Squibb & Sons, L.l.c. · 90 U.S. investigators

    $10.4Mresearch payments

40. Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder

    Completed · Phase 2 · Opioid Use Disorder

    NCT06384157 · Indivior Inc. · 36 U.S. investigators

    $10.4Mresearch payments

41. A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19

    Completed · Phase 3 · COVID-19

    NCT05815498 · ModernaTX, Inc. · 151 U.S. investigators

    $10.2Mresearch payments

42. A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

    Completed · Phase 2 · Obesity

    NCT06683508 · Eli Lilly and Company · 54 U.S. investigators

    $9.7Mresearch payments

43. Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

    Recruiting · Phase 2 · Endometrial Cancer

    NCT05997017 · Aadi Bioscience, Inc. · 8 U.S. investigators

    $9.3Mresearch payments

44. A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

    Active, not recruiting · Phase 3 · Alzheimer Disease

    NCT04437511 · Eli Lilly and Company · 141 U.S. investigators

    $8.4Mresearch payments

45. A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

    Completed · Phase 2 · Obesity

    NCT06603571 · Eli Lilly and Company · 52 U.S. investigators

    $8.2Mresearch payments

46. A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease

    Recruiting · Alzheimer Disease

    NCT06566170 · Eli Lilly and Company · 28 U.S. investigators

    $8.1Mresearch payments

47. A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

    Active, not recruiting · Phase 3 · NASH - Nonalcoholic Steatohepatitis

    NCT03900429 · Madrigal Pharmaceuticals · 74 U.S. investigators

    $8.1Mresearch payments

48. A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)

    Completed · Phase 3 · Obesity

    NCT06584916 · Eli Lilly and Company · 28 U.S. investigators

    $8.1Mresearch payments

49. Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy

    Completed · Phase 2 · Neuropathic Pain

    NCT06568042 · Eli Lilly and Company · 22 U.S. investigators

    $7.8Mresearch payments

50. A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

    Completed · Phase 3 · Type 2 Diabetes

    NCT05803421 · Eli Lilly and Company · 198 U.S. investigators

    $7.8Mresearch payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.